Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, INmune Bio (INMB) has a market cap of $0.17 billion USD. According to our data, INmune Bio is ranked No.7256 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $0.17 B |
64.24%
|
| Dec 31, 2024 | $0.10 B |
-58.53%
|
| Dec 29, 2023 | $0.25 B |
77.60%
|
| Dec 30, 2022 | $0.14 B |
-37.84%
|
| Dec 31, 2021 | $0.23 B |
-40.77%
|
| Dec 31, 2020 | $0.38 B |
196.90%
|
| Dec 31, 2019 | $0.13 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
 Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
 Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
 BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
 Alnylam Pharmaceuticals
ALNY
|
$34.38 B |
-0.000 M
|
USA
|
 Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
 Ionis Pharmaceuticals
IONS
|
$5.13 B |
-0.000 M
|
USA
|
 Moderna
MRNA
|
$14.82 B |
-0.000 M
|
USA
|
 Novavax
NVAX
|
$1.41 B |
-0.000 M
|
USA
|
 Incyte
INCY
|
$13.95 B |
-0.000 M
|
USA
|
 bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
| Market Cap | = | INMB Stock Price | * | INMB Shares Outstanding |
| = | $7.67 | * | 22.17 M | |
| = | $0.17 B |